| Bnd Enterprises, Inc | |
|
513 Se 8th St, College Place, WA 99324-1641 | |
| (509) 200-1284 | |
| Not Available |
| Full Name | Bnd Enterprises, Inc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 513 Se 8th St, College Place, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992917793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | P000000821 (Washington) | Primary |
| Provider Name | William H Hanson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1366574196 PECOS PAC ID: 5395739247 Enrollment ID: I20070426000115 |
News Archive
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Combining 2 tests can improve predictions of severe acute kidney injury in children in intensive care.
Heart defects are the most common type of birth defect, and can be caused by mutations in the gene CHD4. Researchers at the UNC School of Medicine have now revealed key molecular details of how CHD4 mutations lead to heart defects.
Methadone reduces the risk of HIV transmission in people who inject drugs (PWID), as reported by an international team of researchers in a paper published today in the online edition of the British Medical Journal. This team included Dr. Julie Bruneau from the CHUM Research Centre (CRCHUM) and the Department of Family Medicine at the Universit- de Montr-al.
Sosei Group Corporation confirms the information released today by Novartis that results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bnd Enterprises, Inc 513 Se 8th St, College Place, WA 99324-1641 Ph: (509) 200-1284 | Bnd Enterprises, Inc 513 Se 8th St, College Place, WA 99324-1641 Ph: (509) 200-1284 |
News Archive
Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.
Combining 2 tests can improve predictions of severe acute kidney injury in children in intensive care.
Heart defects are the most common type of birth defect, and can be caused by mutations in the gene CHD4. Researchers at the UNC School of Medicine have now revealed key molecular details of how CHD4 mutations lead to heart defects.
Methadone reduces the risk of HIV transmission in people who inject drugs (PWID), as reported by an international team of researchers in a paper published today in the online edition of the British Medical Journal. This team included Dr. Julie Bruneau from the CHUM Research Centre (CRCHUM) and the Department of Family Medicine at the Universit- de Montr-al.
Sosei Group Corporation confirms the information released today by Novartis that results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide.
› Verified 5 days ago